Back to all news
Macro Finance

Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy

CNBC Business·November 18, 2026·1 min read
Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy

Hims & Hers, the telehealth company, has launched new peptide treatments, offering compounded forms of sermorelin, glutathione, NAD+, vitamin B-12, and L-carnitine. None of these are FDA-approved. The company admits there's more to learn about their efficacy, but is moving forward with the products to meet consumer demand.

Read at CNBC Business
Daily crypto arcade

Read the news, then play it.

Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.

Open ChainshortsGet it on the Solana dApp Store